Review of botulinum toxin type A for the prophylactic treatment of chronic daily headache

Stefan EversDepartment of Neurology, University of M&uuml;nster, M&uuml;nster, GermanyAbstract: Botulinum toxin A is increasingly used in the treatment of idiopathic and symptomatic headache disorders. However, only few controlled trials are available and many trials can hardly be co...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Stefan Evers
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2007
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/6cdba5a938434a199a8041bd15a8efbf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6cdba5a938434a199a8041bd15a8efbf
record_format	dspace
spelling	oai:doaj.org-article:6cdba5a938434a199a8041bd15a8efbf2021-12-02T06:27:22ZReview of botulinum toxin type A for the prophylactic treatment of chronic daily headache1176-63281178-2021https://doaj.org/article/6cdba5a938434a199a8041bd15a8efbf2007-05-01T00:00:00Zhttp://www.dovepress.com/review-of-botulinum-toxin-type-a-for-the-prophylactic-treatment-of-chr-a981https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Stefan EversDepartment of Neurology, University of M&uuml;nster, M&uuml;nster, GermanyAbstract: Botulinum toxin A is increasingly used in the treatment of idiopathic and symptomatic headache disorders. However, only few controlled trials are available and many trials can hardly be compared to each other because of different endpoints and different trial designs. In particular chronic daily headache, which is defined as an idiopathic headache occurring on more than 15 days per month for at least 3 months and a daily duration of at least 4 hours, is considered as a headache disorder with possible efficacy of botulinum toxin A. For the prophylactic treatment of chronic tension-type headache and chronic migraine, no sufficient positive evidence for a successful treatment can be obtained from randomized, double-blind, and placebo-controlled trials to date. For the treatment of chronic daily headache including medication overuse headache, there is some positive evidence for efficacy in a subgroup of patients. To date, the majority of double-blind and placebo-controlled studies do not suggest that botulinum toxin A is efficacious in the treatment of chronic idiopathic headache disorders. However, it is possible that some subgroups of patients with chronic daily headache will benefit from a long-term treatment with botulinum toxin A.Keywords: botulinum toxin A, chronic daily headache, chronic tension-type headache, chronic migraine Stefan EversDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2007, Iss Issue 6, Pp 761-764 (2007)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Stefan Evers Review of botulinum toxin type A for the prophylactic treatment of chronic daily headache
description	Stefan EversDepartment of Neurology, University of M&uuml;nster, M&uuml;nster, GermanyAbstract: Botulinum toxin A is increasingly used in the treatment of idiopathic and symptomatic headache disorders. However, only few controlled trials are available and many trials can hardly be compared to each other because of different endpoints and different trial designs. In particular chronic daily headache, which is defined as an idiopathic headache occurring on more than 15 days per month for at least 3 months and a daily duration of at least 4 hours, is considered as a headache disorder with possible efficacy of botulinum toxin A. For the prophylactic treatment of chronic tension-type headache and chronic migraine, no sufficient positive evidence for a successful treatment can be obtained from randomized, double-blind, and placebo-controlled trials to date. For the treatment of chronic daily headache including medication overuse headache, there is some positive evidence for efficacy in a subgroup of patients. To date, the majority of double-blind and placebo-controlled studies do not suggest that botulinum toxin A is efficacious in the treatment of chronic idiopathic headache disorders. However, it is possible that some subgroups of patients with chronic daily headache will benefit from a long-term treatment with botulinum toxin A.Keywords: botulinum toxin A, chronic daily headache, chronic tension-type headache, chronic migraine
format	article
author	Stefan Evers
author_facet	Stefan Evers
author_sort	Stefan Evers
title	Review of botulinum toxin type A for the prophylactic treatment of chronic daily headache
title_short	Review of botulinum toxin type A for the prophylactic treatment of chronic daily headache
title_full	Review of botulinum toxin type A for the prophylactic treatment of chronic daily headache
title_fullStr	Review of botulinum toxin type A for the prophylactic treatment of chronic daily headache
title_full_unstemmed	Review of botulinum toxin type A for the prophylactic treatment of chronic daily headache
title_sort	review of botulinum toxin type a for the prophylactic treatment of chronic daily headache
publisher	Dove Medical Press
publishDate	2007
url	https://doaj.org/article/6cdba5a938434a199a8041bd15a8efbf
work_keys_str_mv	AT stefanevers reviewofbotulinumtoxintypeafortheprophylactictreatmentofchronicdailyheadache
_version_	1718399939207233536

Review of botulinum toxin type A for the prophylactic treatment of chronic daily headache

Ejemplares similares